BioGend Therapeutics (博晟生醫)(6733) 2024Q4 法說會簡報
Company Overview
BioGend Therapeutics (博晟生醫) is a biotech company focused on developing biological regenerative bone materials. The company has two core orthopedic regenerative platforms: RevoCart (愛膝康) and Bone Growth Factor OIF (骨生長因數 OIF). RevoCart is a single-surgery autologous cartilage cell repair technology, while OIF is a bone growth factor with a high cost-performance ratio.
Financial Highlights
The company's financial highlights include:
- Operating revenue of NT$167,648 thousand in 2024, a 52% increase from 2023
- Gross profit of NT$130,508 thousand in 2024, a 45% increase from 2023
- Operating loss of NT$122,260 thousand in 2024, a 31% decrease from 2023
- Net loss after tax of NT$119,940 thousand in 2024, a 25% decrease from 2023
Business Segments
The company's business segments include:
- Orthopedic regenerative products: RevoCart and OIF
- Severe infection products: Minocycline and Fluzole
Products & Technologies
The company's products and technologies include:
- RevoCart (愛膝康): a single-surgery autologous cartilage cell repair technology
- Bone Growth Factor OIF (骨生長因數 OIF): a bone growth factor with a high cost-performance ratio
- Minocycline: an antibiotic for treating severe infections
- Fluzole: an antifungal medication for preventing and treating oral candidiasis
Clients & Markets
The company's clients and markets include:
- Hospitals and medical centers in Taiwan and internationally
- Patients with orthopedic and severe infection conditions
ESG / Sustainability
The company's ESG and sustainability initiatives include:
- Developing innovative products and technologies to improve patient outcomes
- Reducing environmental impact through sustainable manufacturing practices
- Promoting social responsibility through charitable donations and community outreach
Outlook & Strategy
The company's outlook and strategy include:
- Continuing to develop and commercialize innovative orthopedic regenerative products
- Expanding into new markets and geographies
- Building strategic partnerships and collaborations to drive growth and innovation
Additional Data
Additional data and metrics include:
- Revenue growth rate: 52% in 2024
- Gross margin: 78% in 2024
- Operating expense ratio: 151% in 2024
- Net loss per share: NT$0.95 in 2024
- Cash and cash equivalents: NT$219,023 thousand in 2024
- Total assets: NT$912,702 thousand in 2024
- Total liabilities: NT$66,193 thousand in 2024
- Total equity: NT$846,509 thousand in 2024